BACKGROUND: We prospectively evaluated the immunological status, immune recovery and risk of infection in pediatric ALL patients treated on the BFM 95 protocol. PROCEDURE: Humoral and cellular immunity were evaluated in 72 children with ALL at the end of intensive therapy and values were compared to those at the completion of therapy and 6-monthly. Parameters investigated included lymphocyte subpopulation by flow cytometry, immunoglobulin levels by nephelometry, antibody titers to previous immunizations and delayed hypersensitivity with skin testing. Immune responses were correlated to duration of therapy, CNS radiotherapy, age and sex. RESULTS: Humoral immunity was severely depressed by the end of intensive therapy with low immunoglobulin levels and CD19, improved after therapy cessation. Cellular immune responses were normal at the end of intensive treatment but declined significantly by the end of therapy and both CD4 and CD8 remained low at later evaluation points whereas CD4/CD8 ratio was increasing. Duration of therapy and CNS radiotherapy did not affect the rate of immune recovery whereas female had higher CD19, CD45RO, and IgM and children >7 years had higher CD19 and lower CD16 and CD3DR. Among immunized children, 86.7% maintained protective antibodies to MMR and 63% to polio. Despite impairment of immunity, infections outside the neutropenic periods were common viral illnesses. CONCLUSION: Humoral immunity was depressed in children with ALL at the end of intensive therapy but began to recover after cessation of therapy. In contrast, cellular immunity declined significantly by the end of therapy and remained abnormal for at least 1 year post-therapy. (c) 2007 Wiley-Liss, Inc.
BACKGROUND: We prospectively evaluated the immunological status, immune recovery and risk of infection in pediatric ALL patients treated on the BFM 95 protocol. PROCEDURE: Humoral and cellular immunity were evaluated in 72 children with ALL at the end of intensive therapy and values were compared to those at the completion of therapy and 6-monthly. Parameters investigated included lymphocyte subpopulation by flow cytometry, immunoglobulin levels by nephelometry, antibody titers to previous immunizations and delayed hypersensitivity with skin testing. Immune responses were correlated to duration of therapy, CNS radiotherapy, age and sex. RESULTS: Humoral immunity was severely depressed by the end of intensive therapy with low immunoglobulin levels and CD19, improved after therapy cessation. Cellular immune responses were normal at the end of intensive treatment but declined significantly by the end of therapy and both CD4 and CD8 remained low at later evaluation points whereas CD4/CD8 ratio was increasing. Duration of therapy and CNS radiotherapy did not affect the rate of immune recovery whereas female had higher CD19, CD45RO, and IgM and children >7 years had higher CD19 and lower CD16 and CD3DR. Among immunized children, 86.7% maintained protective antibodies to MMR and 63% to polio. Despite impairment of immunity, infections outside the neutropenic periods were common viral illnesses. CONCLUSION: Humoral immunity was depressed in children with ALL at the end of intensive therapy but began to recover after cessation of therapy. In contrast, cellular immunity declined significantly by the end of therapy and remained abnormal for at least 1 year post-therapy. (c) 2007 Wiley-Liss, Inc.
Authors: M Delvecchio; V Cecinati; L P Brescia; M F Faienza; D De Mattia; L Cavallo; N Santoro Journal: J Endocrinol Invest Date: 2009-07-28 Impact factor: 4.256
Authors: Hyo Jin Kwon; Jae-Wook Lee; Nak-Gyun Chung; Bin Cho; Hack-Ki Kim; Jin Han Kang Journal: J Korean Med Sci Date: 2011-12-19 Impact factor: 2.153
Authors: Karen R Rabin; M Monica Gramatges; Michael J Borowitz; Shana L Palla; Xiaodong Shi; Judith F Margolin; Patrick A Zweidler-McKay Journal: Pediatr Blood Cancer Date: 2011-11-18 Impact factor: 3.167
Authors: James L Klosky; Melissa M Hudson; Yanjun Chen; James A Connelly; Karen Wasilewski-Masker; Can-Lan Sun; Liton Francisco; Laura Gustafson; Kathryn M Russell; Gina Sabbatini; Jessica S Flynn; Jocelyn M York; Anna R Giuliano; Leslie L Robison; F Lennie Wong; Smita Bhatia; Wendy Landier Journal: J Clin Oncol Date: 2017-08-24 Impact factor: 44.544
Authors: Evelin A Leibinger; Gábor Pauler; Noémi Benedek; Tímea Berki; István Jankovics; Richard McNally; Gábor Ottóffy Journal: Front Immunol Date: 2021-06-29 Impact factor: 7.561